HALEOSLABS vs MANKIND: Stock Comparison

Haleos Labs Limited vs Mankind Pharma Limited

Live data: 22 July 2026, 3:04 PM IST • Source: NSE and company filings

Mankind Pharma Limited is the larger company by market capitalisation. Haleos Labs Limited shows a lower P/E and a higher dividend yield, while Mankind Pharma Limited shows a higher ROE, faster revenue growth and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Haleos Labs Limited and Mankind Pharma Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, HALEOSLABS is more favourable on 4 of 13 scored metrics and MANKIND on 9These counts are context-free and are not an overall rating.

Key Differences

Market Cap
MANKIND is the larger company
₹1.05 L Cr vs ₹484 Cr
P/E Ratio
HALEOSLABS has a lower P/E
27.94x vs 55.54x
P/B Ratio
HALEOSLABS has a lower P/B
2.27x vs 6.52x
EPS
HALEOSLABS has higher earnings per share
₹57.3 vs ₹46.34
Dividend Yield
HALEOSLABS has a higher dividend yield
0.1% vs 0.04%
Revenue Growth (TTM YoY)
MANKIND has faster revenue growth
11.8% vs 0%
EPS Growth (TTM YoY)
MANKIND has faster EPS growth
31.7% vs 0%
Qtr Sales Growth
MANKIND has stronger quarterly sales growth
11.8% vs -15.7%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricHALEOSLABSMANKIND
SectorHealthcare
IndustryPharmaceuticals

Price

MetricHALEOSLABSMANKIND
Live Price₹1,522.4₹2,545.1
Day Change-3.09%-1.33%
Volume2812.68 L
52-Week High₹1,774₹2,690
52-Week Low₹1,181₹1,909.7
Distance from 52W High-14.18%-5.39%

Valuation

MetricHALEOSLABSMANKIND
Market Cap₹484 Cr₹1.05 L Cr
P/E Ratio27.94x55.54x
P/B Ratio2.27x6.52x
EPS₹57.3₹46.34
Book Value₹706₹395.2
Dividend Yield0.1%0.04%

Growth

MetricHALEOSLABSMANKIND
Revenue Growth (TTM YoY)0%11.8%
EPS Growth (TTM YoY)0%31.7%
Qtr Sales Growth-15.7%11.8%
Qtr Profit Growth-85.2%34.2%

Profitability & Leverage

MetricHALEOSLABSMANKIND
ROE8.44%13.1%
ROCE9.91%13.5%
Net Margin5.33%13.34%
Operating Margin13.4%25.3%
Debt to Equity0.52x0.39x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricHALEOSLABSMANKIND
Promoter Holding72.11%72.66%
FII Holding0%10.24% 1.1 pp
DII Holding0.31% 0.01 pp14.46% 1.21 pp
Public Holding27.58% 0.02 pp2.64% 0.11 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Haleos Labs Limited and Mankind Pharma Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.